166 related articles for article (PubMed ID: 36578414)
21. [Expression of pituitary tumor-transforming gene 1 during the development of androgen-independent prostate cancer].
Cao XL; Song XM; Yu WC; Chen YQ; Wei YY; Liu YL; Lu KQ
Zhonghua Nan Ke Xue; 2016 Aug; 22(8):686-691. PubMed ID: 29019223
[TBL] [Abstract][Full Text] [Related]
22. Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next generation plasma biopsy-based diagnostic biomarkers for inflammatory breast cancer.
Ahmed SH; Espinoza-Sánchez NA; El-Damen A; Fahim SA; Badawy MA; Greve B; El-Shinawi M; Götte M; Ibrahim SA
PLoS One; 2021; 16(4):e0250642. PubMed ID: 33901254
[TBL] [Abstract][Full Text] [Related]
23. α-Actinin-4 Promotes the Progression of Prostate Cancer Through the Akt/GSK-3β/β-Catenin Signaling Pathway.
Park S; Kang M; Kim S; An HT; Gettemans J; Ko J
Front Cell Dev Biol; 2020; 8():588544. PubMed ID: 33363146
[TBL] [Abstract][Full Text] [Related]
24. Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
Wang H; Wei X; Zhang D; Li W; Hu Y
BMC Mol Cell Biol; 2022 Nov; 23(1):51. PubMed ID: 36443669
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of
Zhou W; Shi K; Ji L; Wu R; Chen Y; Tu H; Zhou B; Wang Z; Zhang M
J Cancer; 2018; 9(19):3620-3625. PubMed ID: 30310520
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide analysis of androgen receptor binding sites in prostate cancer cells.
Cheng Y; Yu P; Duan X; Liu C; Xu S; Chen Y; Tan Y; Qiang Y; Shen J; Tao Z
Exp Ther Med; 2015 Jun; 9(6):2319-2324. PubMed ID: 26136980
[TBL] [Abstract][Full Text] [Related]
27. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
28. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
29. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
Li X; Jiao M; Hu J; Qi M; Zhang J; Zhao M; Liu H; Xiong X; Dong X; Han B
Prostate; 2020 Jun; 80(9):674-686. PubMed ID: 32294305
[TBL] [Abstract][Full Text] [Related]
30. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.
Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R
Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697
[TBL] [Abstract][Full Text] [Related]
31. Combination of miR-99b-5p and Enzalutamide or Abiraterone Synergizes the Suppression of EMT-Mediated Metastasis in Prostate Cancer.
Waseem M; Wang BD
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792011
[TBL] [Abstract][Full Text] [Related]
32. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
33. Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression.
Chen H; Zhao L; Meng Y; Qian X; Fan Y; Zhang Q; Wang C; Lin F; Chen B; Xu L; Huang W; Chen J; Wang X
Cancer Lett; 2022 Jun; 536():215611. PubMed ID: 35240233
[TBL] [Abstract][Full Text] [Related]
34. [Expression and regulation of androgen receptor in the androgen-independent conversion of prostate cancer cells].
Wang HF; Liu WJ; Jin J; Zhou LQ; Liang LL; Wang Y; Guo YL
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):490-5. PubMed ID: 21844951
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6 induced overexpression of valosin-containing protein (VCP)/p97 is associated with androgen-independent prostate cancer (AIPC) progression.
Duscharla D; Reddy Kami Reddy K; Dasari C; Bhukya S; Ummanni R
J Cell Physiol; 2018 Oct; 233(10):7148-7164. PubMed ID: 29693262
[TBL] [Abstract][Full Text] [Related]
36. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
37. [Downregulation of PTTG1 expression inhibits the proliferation and invasiveness and promotes the apoptosis of human prostate cancer LNCaP-AI cells].
Cao XL; Wei YY; Song XM; Lu KQ; Yu WC; Chen YQ; Liu YL; Gao JP
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):589-597. PubMed ID: 29723450
[TBL] [Abstract][Full Text] [Related]
38. Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance.
Zhong S; Huang C; Chen Z; Chen Z; Luo JL
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768524
[TBL] [Abstract][Full Text] [Related]
39. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
40. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
